| Drug Name: | Lenvatinib |
|---|
| Drug Class: | Tyrosine kinase inhibitor |
|---|
| Mechanism of Action: | Inhibits multiple receptor tyrosine kinases, including VEGFR, FGFR, PDGFR, RET, and KIT |
|---|
| Use: | - Treatment of advanced renal cell carcinoma
- Treatment of unresectable hepatocellular carcinoma
- Treatment of radioactive iodine-refractory differentiated thyroid cancer
|
|---|
| Side Effects: | - Hypertension
- Fatigue
- Diarrhea
- Nausea
- Decreased appetite
- Weight loss
- Proteinuria
- Hand-foot syndrome
- QT prolongation
|
|---|
| Contraindications: | - Pregnancy
- Breastfeeding
- Severe hepatic impairment
|
|---|
| Specialty: | - Oncology
- Hepatology
- Endocrinology
|
|---|